{
    "clinical_study": {
        "@rank": "166557", 
        "arm_group": [
            {
                "arm_group_label": "cefoperazone + metronidazole", 
                "arm_group_type": "Experimental", 
                "description": "cefoperaozone 2g q8h + MDZ 0.5g q8h Oral care Somatostatin 3-6mg per 24h enteral nutrition"
            }, 
            {
                "arm_group_label": "meropenem", 
                "arm_group_type": "Active Comparator", 
                "description": "Meropenem 0.5g q6h or adapted with renal function. Oral care Somatostatin 3-6mg per 24h enteral nutrition"
            }
        ], 
        "brief_summary": {
            "textblock": "Strategy of antibiotic therapy in SAP,De-escalate (cefoperazone+metronidazole) or Escalate\n      (meropenem) therapy,which one is better."
        }, 
        "brief_title": "Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatitis,Acute Necrotizing", 
        "condition_browse": {
            "mesh_term": [
                "Pancreatitis", 
                "Pancreatitis, Acute Necrotizing"
            ]
        }, 
        "detailed_description": {
            "textblock": "SAP is a serious and life-threatening disease and requires intensive and aggressive\n      management of multiple organ failure and severe infectious complications that can develop in\n      these patients. The most common cause of death in patients suffering from severe acute\n      pancreatitis (SAP) is the infection of pancreatic necrosis by enteric bacteria with\n      mortality rates of 30% (range 14- 62%),spurring the discussion of whether or not\n      prophylactic antibiotic administration could be a beneficial approach. Pancreatic infections\n      are more often monomicrobial, especially E. coli in the two first weeks (100% and 62.5%) of\n      onset, with a shift from gram-negative to gram-positive as the pancreatitis progressed.\n\n      In order to evaluate the benefit of prophylactic antibiotic application, a number of\n      randomized controlled clinical trials have been published over the past 15 years. Since the\n      results were conflicting and most studies were of low methodological quality and/or\n      statistically underpowered, meta-analyses have been performed to assess this important\n      issue. However, their results ranged from absolutely no effect of antibiotic prophylaxis to\n      positive effects regarding mortality, the incidence of infected pancreatic necrosis and the\n      incidence of extra pancreatic infections.\n\n      In order to provide reliable evidence of the effect of antibiotherapy strategy in SAP, we\n      performed a prospective randomized multicenter clinical trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  severe Acute Pancreatitis according to Atlanta criteria revisited in 2012\n\n        Exclusion Criteria:\n\n          -  concurrent sepsis or (peri)pancreatic infection caused by a second disease\n\n          -  patients with chronic organ failure (chronic renal failure needs kidney replacement,\n             chronic heart failure, decompensate hepatic cirrhosis, chronic obstructive pulmonary\n             disease)\n\n          -  recurrent or endoscopic retrograde cholangiopancreatography (ERCP), or traumatic or\n             operative pancreatitis\n\n          -  pregnancy, malignancy or immunodeficiency\n\n          -  a history of allergy to meropenem, cefoperazone and metronidazole\n\n          -  a history of antibiotic administration within 48 h prior to enrollment\n\n          -  possible death within 48 h after enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992198", 
            "org_study_id": "SAP BUNDLE-ANTIBIOTICS", 
            "secondary_id": "12411950500"
        }, 
        "intervention": [
            {
                "arm_group_label": "meropenem", 
                "description": "1.Clinical parameters (2 of 3):\n1)temperature<37.8\u2103 or 2)HR <100bpm or 3)SpO2 >95% 2.Laboratory parameters (3 of 3):\n1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC <12\u00d710E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed <30% compared to that of 72h", 
                "intervention_name": "cefoperazone + metronidazole", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cefobid", 
                    "Metronidazole"
                ]
            }, 
            {
                "arm_group_label": [
                    "cefoperazone + metronidazole", 
                    "meropenem"
                ], 
                "description": "oral care by 0.2% chlorhexidine gluconate twice daily", 
                "intervention_name": "oral care by chlorhexidine gluconate", 
                "intervention_type": "Procedure", 
                "other_name": "chlorhexidine gluconate"
            }, 
            {
                "arm_group_label": [
                    "cefoperazone + metronidazole", 
                    "meropenem"
                ], 
                "intervention_name": "enteral nutrition", 
                "intervention_type": "Procedure", 
                "other_name": "Enteral Nutritional Suspension(SP) by NUTRICIA"
            }, 
            {
                "arm_group_label": [
                    "cefoperazone + metronidazole", 
                    "meropenem"
                ], 
                "intervention_name": "Somatostatin", 
                "intervention_type": "Drug", 
                "other_name": "somatostatin by merk"
            }, 
            {
                "arm_group_label": "cefoperazone + metronidazole", 
                "description": "All patients in cefo-group do not meet 1 of 3 laboratory parameter or image parameter or 2 of 3 clinical parameters.\n1.Clinical parameters (2 of 3):\n1)temperature<37.8\u2103 or 2)HR <100bpm or 3)SpO2 >95% 2.Laboratory parameters (3 of 3):\n1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC <12\u00d710E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed <30% compared to that of 72h", 
                "intervention_name": "Meropenem", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cefoperazone", 
                "Meropenem", 
                "Sulperazone", 
                "Chlorhexidine gluconate", 
                "Chlorhexidine", 
                "Metronidazole", 
                "Somatostatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "antibiothearpy strategy", 
            "cefoperazone", 
            "metronidazole", 
            "meropenem"
        ], 
        "lastchanged_date": "November 18, 2013", 
        "location": {
            "contact": {
                "last_name": "Erzhen Chen, M.D", 
                "phone": "86-13901753478"
            }, 
            "contact_backup": {
                "last_name": "Enqiang , Mao", 
                "phone": "86-13501747906"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200025"
                }, 
                "name": "Depatrment of EICU,Ruijin Hospital"
            }, 
            "investigator": {
                "last_name": "Zhitao Yang, M.D", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis", 
        "overall_contact": {
            "last_name": "Erzhen Chen, M.D", 
            "phone": "86-13901753478"
        }, 
        "overall_contact_backup": {
            "last_name": "Enqiang Mao, M.D", 
            "phone": "86-13501747906"
        }, 
        "overall_official": [
            {
                "affiliation": "Ruijin Hospital", 
                "last_name": "Er-Zhen Chen, M.D. & Ph.D.", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Ruijin Hospital", 
                "last_name": "En-Qiang Mao, M.D. & Ph.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Ruijin Hospital", 
                "last_name": "Zhi-Tao Yang, M.D. & Ph.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Science and Technology Commission of Shanghai Municipality", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "pancreatic or peripancreatic infection", 
            "safety_issue": "Yes", 
            "time_frame": "28-day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992198"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ruijin Hospital", 
            "investigator_full_name": "Erzhen Chen", 
            "investigator_title": "Professer", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "cost of management of SAP", 
                "safety_issue": "No", 
                "time_frame": "90-day"
            }, 
            {
                "description": "sputum, urine and blood culture will be done once or twice per week if needed. bill or other culutre will be done when the patient is undergoing operation.", 
                "measure": "Microbiology resistance", 
                "safety_issue": "Yes", 
                "time_frame": "90-day"
            }
        ], 
        "source": "Ruijin Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "RenJi Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Erzhen Chen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}